Maity, Amit
Mick, Rosemarie
Huang, Alexander C.
George, Sangeeth M.
Farwell, Michael D.
Lukens, John N.
Berman, Abigail T.
Mitchell, Tara C.
Bauml, Josh
Schuchter, Lynn M.
O’Hara, Mark
Lin, Lilie L.
Demichele, Angela
Christodouleas, John P.
Haas, Naomi B.
Patsch, Dana M.
Hahn, Stephen M.
Minn, Andy J.
Wherry, E. John
Vonderheide, Robert H.
Article History
Received: 19 May 2018
Revised: 30 August 2018
Accepted: 11 September 2018
First Online: 15 October 2018
Competing interests
: Merck, which manufactures pembrolizumab, provided the drug for free and provided personnel support via an investigator-sponsored research agreement to A.M. The authors declare no competing interests.
: The study and amendments were approved by the University of Pennsylvania institutional review board (protocol 821403). All patients signed consent to participate in the trial and to have their information used in future publications.
: This work was supported by the National Institutes of Health (P50 CA174523 SPORE grant pilot award to A.M., P01-CA-210944 to R.H.V., A.M., A.J.M. and E.J.W., P30-CA-016520 Cancer Center Support Grant) and Merck.
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International licence (CC BY 4.0).